CELMoDs on the Horizon: A New Chapter in Lymphoma Care

In this podcast, 2 experts explore the evolving role of CELMoD-based strategies in lymphoma, with a focus on the biologic mechanisms and emerging clinical evidence for golcadomide in diffuse large B-cell lymphoma and follicular lymphoma. Listeners will hear how CELMoDs differ from established immunomodulatory and immune-based therapies, review evidence from ongoing and early-phase studies of golcadomide as monotherapy and in combination regimens, and consider practice-relevant issues including efficacy, toxicity, treatment sequencing, combination strategies, and the experts’ thoughts on how emerging CELMoD therapy can be adopted into community-based lymphoma care.